Mary Pat Petrillo

2 papers in the library · 5 citations · publishing 2023-2024

Papers

Sort Most recent Most cited

Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.

CNS Spectrums June 1, 2024 Jennifer Kern Sliwa, Ronaldo R Naranjo, Ibrahim Turkoz et al. 5 citations

To examine the effect of esketamine nasal spray (ESK) plus newly initiated oral antidepressant (OAD) versus OAD plus placebo nasal spray (PBO) on the association between Montgomery-Åsberg Depression Rating Scale (MADRS) and 9-item Patient Health Questionnaire (PHQ-9) scores in adults with treatment-resistant depression (TRD). Data from TRANSFORM-1 and TRANSFORM-2 (two similarly designed,...

DOI: 10.1017/S1092852924000105 Full text Esketamine nasal spray Oral antidepressant Severity Treatment resistant +5

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.

CNS Drugs August 9, 2023 Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi et al.

Background: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK...

DOI: 10.1007/s40263-023-01026-3 Full text Ketamine Humans Antidepressive agents Treatment outcome +5